Travis Ferguson
Pulmonary Disease · Baltimore, MDNPI 1346698289
Payments from drug & device makers
Across 31 payments — averaging $125.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Johnson & Johnson$1K
- Medtronic$300
- ERBE USA Inc$209
- Inari Medical, Inc.$149
- Pulmonx Corporation$137
- plus $305 from 4 others
What the payments were for
- Travel & lodging$84622%
- Food & beverage$1,54040%
- Education$1,50039%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $1,761 |
| Johnson & Johnson | 12 | $1,024 |
| Medtronic | 3 | $300 |
| ERBE USA Inc | 2 | $209 |
| Inari Medical, Inc. | 1 | $149 |
| Pulmonx Corporation | 2 | $137 |
| AstraZeneca | 1 | $128 |
| Sanofi | 1 | $104 |
| Olympus America Inc. | 1 | $59 |
| Ambu Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,500
- Monarch Platform$827
- FLOWTRIEVER CATHETER, S$298
- Erbe VIO APC CRYO$160
- Arcpoint$157
- IMFINZI$128
- CHARTIS CATHETER$106
- ZEPHYR DELIVERY CATHETER$106
- ZEPHYR ENDOBRONCHIAL VALVE$106
- PULMONX CHARTIS TABLET CONSOLE$106
- ILLUMISITE$100
How this compares
$3,885 in reported general payments places this provider in the 60th percentile of 297 pulmonary disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $112,586 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $22,709 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,395 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,730 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,178 |
| Montelukast Sodium | 13 | $264 |
| Azithromycin | 12 | $78 |
| Prednisone | 16 | $33 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Baltimore
- Alan SchwartzBaltimore$1.6M
- Sonye DanoffBaltimore$1.5M
- Michael DrummondBaltimore$1.4M
- Paul HassounBaltimore$1.3M
- Lonny YarmusBaltimore$1.2M
- Jonathan SevranskyBaltimore$971K
- Robert WiseBaltimore$761K
- Nancy LinBaltimore$758K
- Hitesh BatraBaltimore$690K
- Mark LiuBaltimore$503K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.